David is an accomplished IP attorney with over 15 years of experience prosecuting, advising, and litigating in various technology areas, including pharmaceuticals, chemical, biologics, diagnostics, gene editing, and medical devices. 

David specializes in patent litigation, including litigating many high-profile and billion-dollar patent cases in district court litigation, Federal Circuit appeals, and Patent Trial and Appeal Board (PTAB) proceedings. David has counseled his clients through all aspects of litigation, including arguing claim construction and discovery-related issues before the Court, taking and defending dozens of fact and expert depositions, and taking numerous direct and cross examinations of expert witnesses at trial. In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”

In particular, David has extensive experience litigating pharmaceutical patent matters under the Biologics Price Competition and Innovation Act (BPCIA) and Hatch-Waxman Act, including representing patentees, biosimilars, and generic filers. His representative BPCIA matters include litigating Prolia® (denosumab), Xgeva® (denosumab), Stelara® (ustekinumab), Avastin® (bevacizumab), Herceptin® (trastuzumab), and Rituxan® (rituximab). 

His representative Hatch-Waxman / ANDA matters include litigating Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).

In addition, David has represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (TDF).

David also maintains an active pro bono practice focusing on advocating for LGBTQ+ equality. He has filed administrative complaints under the Federal Tort Claims Act, prepared and filed asylum applications and supporting documentation, and submitted petitions for legal name changes.

Prior to joining Mintz, David was a senior counsel in the Litigation Department’s Life Sciences Group at an international law firm. Earlier, he practiced at another global law firm.

In law school, David served as the lead article editor of the Minnesota Journal of Law, Science & Technology.